once weekly glp 1 agonist GLP-1 Agonists - What is it? GLP-1 Receptor Agonist Market Growth
Description
The SUSTAIN 6 trial, in particular, demonstrated a 26% reduction in the risk of major cardiovascular events compared to the standard treatment
Claim CME for this episode HERE
Endocr Relat Cancer
In order to be eligible for compensation, the consumer must meet the following criteria: You must have a strong claim to be eligible for damage compensation
However, there some key differences in the weight loss impacts between the 2 treatments
However, the evidence supporting their use specifically in patients post-bariatric surgery remains limited, with findings from individual studies not yet justifying widespread clinical adoption
